Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas

Journal of Translational Medicine

Giuseppe Palmieri⁴  Antonio Cossu¹  MariaCristina Sini⁴  Maria Colombino⁴  Ignazio Stanganelli²  Corrado Caracò³  Gerardo Botti³  Paolo A Ascierto³  Mariaelena Capone³  Amelia Lissia¹  Antonella Manca⁴ 

[1] Department of Pathology, Hospital-University Health Unit (AOU), Sassari, Italy;Skin Cancer Unit, Istituto Scientifico Romagnolo Tumori (IRST), Meldola, Italy;Istituto Nazionale Tumori, Fondazione Pascale, Naples, Italy;Institute of Biomolecular Chemistry, National Research Council (CNR), Traversa La Crucca 3 - Baldinca Li Punti, Sassari, 07100, Italy

关键词: Resistance to BRAF/MEK inhibitors;    PIK3CA gene;    Mutation analysis;    Melanoma;   

Others  :  1137692
DOI  :  10.1186/s12967-015-0401-8

 received in 2014-11-17, accepted in 2015-01-15,  发布年份 2015

【 摘 要 】

Background

Activated PI3K-AKT pathway may contribute to decrease sensitivity to inhibitors of key pathogenetic effectors (mutated BRAF, active NRAS or MEK) in melanoma. Functional alterations are deeply involved in PI3K-AKT activation, with a minimal role reported for mutations in PIK3CA, the catalytic subunit of the PI3K gene. We here assessed the prevalence of the coexistence of BRAF/NRAS and PIK3CA mutations in a series of melanoma samples.

Methods

A total of 245 tumor specimens (212 primary melanomas and 33 melanoma cell lines) was screened for mutations in BRAF, NRAS, and PIK3CA genes by automated direct sequencing.

Results

Overall, 110 (44.9%) samples carried mutations in BRAF, 26 (10.6%) in NRAS, and 24 (9.8%) in PIK3CA. All identified PIK3CA mutations have been reported to induce PI3K activation; those detected in cultured melanomas were investigated for their interference with the antiproliferative activity of the BRAF-mutant inhibitor vemurafenib. A reduced suppression in cell growth was observed in treated cells carrying both BRAF and PIK3CA mutations as compared with those presenting a mutated BRAF only. Among the analysed melanomas, 12/245 (4.9%) samples presented the coexistence of PIK3CA and BRAF/NRAS mutations.

Conclusions

Our study further suggests that PIK3CA mutations account for a small fraction of PI3K pathway activation and have a limited impact in interfering with the BRAF/NRAS-driven growth in melanoma.

【 授权许可】

   
2015 Manca et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al.: Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-54.
• [2]Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al.: Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-47.
• [3]Palmieri G, Capone ME, Ascierto ML, Gentilcore G, Stroncek DF, Casula M, et al.: Main roads to melanoma. J Transl Med 2009, 7:86. BioMed Central Full Text
• [4]Janku F, Lee JJ, Tsimberidou AM, Hong DS, Naing A, Falchook GS, et al.: PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 2011, 6:e22769.
• [5]Shull AY, Latham-Schwark A, Ramasamy P, Leskoske K, Oroian D, Birtwistle MR, et al.: Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One 2012, 7:e43369.
• [6]Vivanco I, Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501.
• [7]Plas DR, Thompson CB: Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005, 24:7435-42.
• [8]Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, Calabrò L, Cascinelli N, et al.: Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”. J Transl Med 2013, 11:137. BioMed Central Full Text
• [9]Van Allen EM, Wagle N, Sucker A, Treacy DJ, Johannessen CM, Goetz EM, et al.: The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014, 4:94-109.
• [10]Hartsough E, Shao Y, Aplin AE: Resistance to RAF inhibitors revisited. J Invest Dermatol 2014, 134:319-25.
• [11]Slominski AT, Carlson JA: Melanoma resistance: a bright future for academicians and a challenge for patient advocates. Mayo Clin Proc 2014, 89:429-33.
• [12]Slominski A, Kim TK, Brożyna AA, Janjetovic Z, Brooks DL, Schwab LP, et al.: The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways. Arch Biochem Biophys 2014, 563:79-93.
• [13]Slominski A, Zmijewski MA, Pawelek J: L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell Melanoma Res 2012, 25:14-27.
• [14]Chen J, Shen Q, Labow M, Gaither LA: Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling. Cancer Res 2011, 71:4280-91.
• [15]Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al.: Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-74.
• [16]Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, et al.: The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012, 18:2316-25.
• [17]Mao M, Tian F, Mariadason JM, Tsao CC, Lemos R Jr, Dayyani F, et al.: Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res 2013, 19:657-67.
• [18]Cheung M, Sharma A, Madhunapantula SV, Robertson GP: Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 2008, 68:3429-39.
• [19]Tran MA, Gowda R, Sharma A, Park EJ, Adair J, Kester M, et al.: Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development. Cancer Res 2008, 68:7638-49.
• [20]Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, et al.: Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 2012, 11:909-20.
• [21]Xing F, Persaud Y, Pratilas CA, Taylor BS, Janakiraman M, She QB, et al.: Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring (V600E)BRAF. Oncogene 2012, 31:446-57.
• [22]Carli P, De Giorgi V, Chiarugi A, Stante M, Giannotti B: Multiple synchronous cutaneous melanomas: implications for prevention. Int J Dermatol 2002, 41:583-5.
• [23]Casula M, Colombino M, Satta MP, Cossu A, Ascierto PA, Bianchi-Scarrà G, et al.: BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility. J Clin Oncol 2004, 22:286-92.
• [24]Palomba G, Colombino M, Contu A, Massidda B, Baldino G, Pazzola A, et al.: Prevalence of KRAS, BRAF, and PIK3CA somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia. J Transl Med 2012, 10:178. BioMed Central Full Text
• [25]Manca A, Sini MC, Izzo F, Ascierto PA, Tatangelo F, Botti G, et al.: Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncol Rep 2011, 25:1495-502.
• [26]Casula C, Muggiano A, Cossu A, Budroni M, Caracò C, Ascierto PA, et al.: Role of key-regulator genes in melanoma susceptibility and pathogenesis among patients from South Italy. BMC Cancer 2009, 9:352. BioMed Central Full Text
• [27]Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, et al.: BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol 2012, 30:2522-9.
• [28]Colombino M, Lissia A, Capone M, De Giorgi V, Massi D, Stanganelli I, et al.: Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. J Transl Med 2013, 11:202. BioMed Central Full Text
• [29]Gopal YN, Deng W, Woodman SE, Komurov K, Ram P, Smith PD, et al.: Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 2010, 70:8736-47.
• [30]Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, et al.: PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011, 71:2750-60.
• [31]Byron SA, Loch DC, Wellens CL, Wortmann A, Wu J, Wang J, et al.: Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant BRAF and wild-type PTEN status. Mol Cancer 2012, 11:75. BioMed Central Full Text
• [32]Deng W, Gopal YN, Scott A, Chen G, Woodman SE, Davies MA: Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res 2012, 25:248-58.
• [33]Spagnolo F, Ghiorzo P, Queirolo P: Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget 2014, 5:10206-21.
• [34]Curtin JA, Stark MS, Pinkel D, Hayward NK, Bastian BC: PI3-kinase subunits are infrequent somatic targets in melanoma. J Invest Dermatol 2006, 126:1660-3.
• [35]Omholt K, Kröckel D, Ringborg U, Hansson J: Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res 2006, 16:197-200.
• [36]Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al.: A landscape of driver mutations in melanoma. Cell 2012, 150:251-63.
• [37]Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, et al.: Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012, 44:1006-14.
• [38]Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, et al.: Clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 2015, 135:508-15.
• [39]Davies MA, Stemke-Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, et al.: A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer 2008, 99:1265-8.
• [40]Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, et al.: Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 2012, 26:1055-69.
• [41]Nogueira C, Kim KH, Sung H, Paraiso KH, Dannenberg JH, Bosenberg M, et al.: Cooperative interactions of PTEN deficiency and RAS activation in melanoma metastasis. Oncogene 2010, 29:6222-32.
• [42]Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, et al.: Whole genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol 2014, 25:959-67.